Scientists Report First use of CRISPR to Substitute Genes to Treat Patients with CancerNovember 23, 2022
For the first time, scientists have used CRISPR gene editing technology to substitute a gene to treat patients with cancer. The new approach first identifies T cells that specifically recognize and kill an individual patient's tumor cells.
T cells are a type of immune cell, and the cells in question kill tumor cells when they encounter specific genetic mutations from cancer. However, there are often not enough of these cells. By CRISPR editing other T cells from the patient with the same cancer recognition motifs, the approach is designed to build a large army of cancer-fighting cells, which are then infused back into the patient, thus greatly amplifying that natural anti-tumor response.
The therapy approach was developed by PACT Pharma, based upon the work pioneered by Dr. Jim Heath, president of the Institute for Systems Biology (ISB), and his collaborators, UCLA Professor Dr. Toni Ribas and Caltech Professor Dr. David Baltimore. The therapy was used to treat 16 patients. The early-stage clinical trials were meant to show that the treatment was safe for patients, but the researchers also found that the engineered T cells did, in fact, home in on the patient tumors.
“This is a leap forward in developing a personalized treatment for cancer,” Ribas said. “The generation of a personalized cell treatment for cancer would not have been feasible without the newly developed ability to use the CRISPR technique to replace the immune receptors in clinical-grade cell preparations in a single step,” he added.
You might also like:
- Plant Growth Study Sheds Light on Cancer Research
- Study Shows Link between CRISPR and Mutated Cancer Cells
- UK Scientists Develop Genome-edited Wheat to Reduce Cancer Risk from Bread
The Crop Biotech Update is a weekly newsletter of ISAAA, a not-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- Codex Alimentarius Commission Adopts New Food Safety Standards
- Kenyans Need to Turn to GM Crops to Combat Drought
- 28-Million-Year-Old Gene Protects Plants Against Caterpillars
- Agronomists Find Wheat Varieties Resistant to Enzyme Depletion
- Philippines Celebrate 18th National Biotech Week
- ISAAA Inc., SEARCA Launches Policy Briefs on Philippine Biosafety Regulations As Part of the National Biotechnology Week Celebration
- EFSA GMO Panel Concludes GM Maize MON 87429 Safe as Conventional Counterpart
- Root Structure Mapped Out to Identify Components of Drought Stress Tolerance in Rice
Read the latest:
- Crop Biotech Update (December 1, 2022)
- Genome Editing Supplement (November 23, 2022)
- Gene Drive Supplement (December 1, 2022)
Subscribe to CBU: